Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqCM - Nasdaq Real Time Price USD

Beyond Air, Inc. (XAIR)

Compare
0.2361
-0.0055
(-2.28%)
At close: April 7 at 4:00:00 PM EDT
0.2368
+0.00
+(0.30%)
After hours: April 7 at 6:03:14 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Steven Adam Lisi CEO & Chairman of the Board 650k -- 1971
Mr. Michael A. Gaul Chief Operating Officer 400k -- 1955
Mr. Amir Avniel Chief Executive Officer of NeuroNOS 496k -- 1974
Mr. Douglas Quinton Larson CFO, Principal Financial Officer & Principal Accounting Officer 274.95k -- 1970
Dr. Andrew R. Colin M.D. Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board -- -- --
Mr. David R. Webster Chief Commercial Officer -- -- 1967
Dr. John Jett Ph.D. Head of Research & Clinical Development -- -- --
Mr. Adam Newman Corporate Secretary 250k -- --

Beyond Air, Inc.

900 Stewart Avenue
Suite 301
Garden City, NY 11530
United States
516 665 8200 https://www.beyondair.net
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
107

Description

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Corporate Governance

Beyond Air, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

June 23, 2025 at 10:59 AM UTC - June 27, 2025 at 12:00 PM UTC

Beyond Air, Inc. Earnings Date

Recent Events

March 28, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 14, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 14, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 10, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

February 6, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 5, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 31, 2025 at 12:00 AM UTC

S-3: Offering Registrations

December 20, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 13, 2024 at 12:00 AM UTC

S-8: Offering Registrations

December 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers